How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    • Has all of the relevant evidence been taken into account?

  • Question on Consultation

    • Are the summaries of clinical and and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    • Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    • Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of race, gender, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Finerenone for treating chronic kidney disease in type 2 diabetes

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about finerenone

Marketing authorisation indication

2.1 Finerenone (Kerendia, Bayer) is indicated 'for the treatment of chronic kidney disease (stage 3 and 4 with albuminuria) associated with type 2 diabetes in adults.'

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics for finerenone.

Price

2.3 The indicative list price of finerenone is £55.20 for a 30-day supply of 30 tablets, for both 10 mg and 20 mg doses, and a daily cost of £1.84 (excluding VAT, company submission). Costs may vary in different settings because of negotiated procurement discounts.